With their strategic partnership, the bioinformatics firms seek to "break the biomarker bottleneck" that is holding back the potential of multi-omics research.
Franklin, an AI-driven variant classification tool, is helping Sanford Imagenetics reduce variants of unknown significance in its new ACMG-59 genotyping test.
While "genomical" has not supplanted "astronomical" in the lexicon, geneticist Gene Robinson believes data scientists understand the sheer size of genomic information.
Dana-Farber's MatchMiner adds structure to clinical trial data to automate the pairing of patient genomic profiles to specific cancer research.
Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.
British bioinformatics company Genestack hopes to overcome omics data fragmentation and inefficiencies in drug discovery with extensions to its NGS data platform.
The University of Nebraska Medical Center has created a SNOMED-CT and LOINC extension to make a cancer pathology report as "readily presentable as a CBC."
"Repurposing starts with the human genome," a precision medicine expert said in explaining Vanderbilt's new approach to accelerating clinical trials.
A study led by Johns Hopkins describes a method for automating slow, inaccurate manual chart review when searching for signs of misdiagnosis.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.